RT Journal Article
SR Electronic
T1 Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD: NOVELTY study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 2990
DO 10.1183/13993003.congress-2020.2990
VO 56
IS suppl 64
A1 Müllerová, Hana
A1 Finch, Donna K
A1 Agustí, Alvar
A1 Alacqua, Marianna
A1 Anderson, Gary P
A1 Beasley, Richard
A1 Belton, Laura
A1 De Giorgio-Miller, Alex
A1 Fitzgerald, J Mark
A1 Hughes, Rod
A1 Pavord, Ian D
A1 Price, David
A1 Rapsomaniki, Eleni
A1 Sadatsafavi, Mohsen
A1 Vestbo, Jørgen
A1 Bel, Elisabeth H
YR 2020
UL https://publications.ersnet.org//content/56/suppl_64/2990.abstract
AB Background: Blood eosinophil count (bEOS) is an important biomarker in obstructive lung disease. NOVELTY (NCT02760329) is a global, prospective, observational study with potential to identify obstructive lung disease phenotypes associated with differential outcomes, using biomarkers and clinical features.Objective: To evaluate factors associated with bEOS in patients with either physician-assigned asthma or COPD in NOVELTY.Methods: A cross-sectional analysis of associations between a single bEOS measurement and other baseline characteristics was performed using univariate and multivariate regression models.Results: Of 4,538 patients with data, the geometric mean (SE) bEOS was 0.16 (0.002) x109/L. Of these, 864 (19%) had EOS ≥300 cells/µL (23% asthma; 14% COPD). High bEOS was positively associated with male sex, ≥2 symptom worsenings in prior 3 months, FeNO, FEV1 reversibility, obesity and frequent mucoid cough, in both asthma and COPD (Figure). For asthma, positive associations with higher bEOS were observed for reduced lung function and physician-assessed severity; for COPD, positive associations were observed with current/former smokers. Associations with FeNO and frequent mucoid cough persisted in multivariate models for both diagnoses.Conclusions: Higher bEOS was independently associated with higher FeNO and presence of frequent mucoid cough regardless of physician-assigned asthma or COPD.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2990.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).